Company news

Castle Biosciences, Inc. news in 2026

Castle Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Castle Biosciences Reports Third Quarter 2026 Results

November 5, 2026

Castle Biosciences to Participate in Upcoming Investor Conferences

October 28, 2026

Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

October 15, 2026

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

October 12, 2026

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

September 30, 2026

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

September 28, 2026

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

September 24, 2026

Castle Biosciences to Open New Laboratory Facility in Scottsdale

September 22, 2026

New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

September 15, 2026

JAAD Publication Shows Improved Performance of DecisionDx®-SCC

September 9, 2026

Castle Biosciences: Approved for Dual Listing on Nasdaq Texas

August 17, 2026

Castle Biosciences Reports Second Quarter 2026 Results

July 30, 2026

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference

July 22, 2026

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test

July 15, 2026

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

July 14, 2026

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

July 9, 2026

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

July 9, 2026

Castle Biosciences: DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

June 25, 2026

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

June 23, 2026

Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

June 16, 2026

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

May 13, 2026

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

May 12, 2026

Castle Biosciences Reports First Quarter 2026 Results

May 6, 2026

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

May 5, 2026

New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

May 4, 2026

Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

April 21, 2026

Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

April 15, 2026

Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year

April 10, 2026

Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

March 26, 2026

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

March 13, 2026

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

March 8, 2026

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

March 4, 2026

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

March 3, 2026

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

February 26, 2026

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

February 18, 2026

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

February 4, 2026

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

January 10, 2026

Calls in 2026

Decks in 2026